Used in targeted therapy for B-cell malignancies, particularly relapsed or refractory acute lymphoblastic leukemia (ALL). The antibody binds specifically to CD22, a surface antigen on B-cells, enabling selective delivery of cytotoxic agents when conjugated to drugs like calicheamicin. This targeted approach minimizes damage to healthy cells, improving treatment efficacy and reducing systemic toxicity. Also investigated in immunotherapy regimens and antibody-drug conjugate (ADC) development for hematologic cancers.